These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

604 related items for PubMed ID: 18282018

  • 1. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K, Plosker GL.
    Pharmacoeconomics; 2008; 26(3):251-68. PubMed ID: 18282018
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, Lewis G.
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [Abstract] [Full Text] [Related]

  • 3. Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
    Dhillon S, Lyseng-Williamson KA.
    Drugs; 2008 Aug; 68(4):507-34. PubMed ID: 18318568
    [Abstract] [Full Text] [Related]

  • 4. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.
    J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
    [Abstract] [Full Text] [Related]

  • 5. Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.
    Carter JA, Joshi AD, Kaura S, Botteman MF.
    Pharmacoeconomics; 2012 May; 30(5):373-86. PubMed ID: 22500986
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
    De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, Lewis G.
    Support Care Cancer; 2005 Dec; 13(12):975-86. PubMed ID: 15871033
    [Abstract] [Full Text] [Related]

  • 7. Zoledronic acid: a review of its use in patients with advanced cancer.
    Perry CM, Figgitt DP.
    Drugs; 2004 Dec; 64(11):1197-211. PubMed ID: 15161327
    [Abstract] [Full Text] [Related]

  • 8. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
    Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, Timmins H, Wheatley D, Grieve R, Griffiths G, Murray N.
    Lancet Oncol; 2014 Jan; 15(1):114-22. PubMed ID: 24332514
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K.
    J Med Econ; 2012 Jan; 15(4):712-23. PubMed ID: 22409231
    [Abstract] [Full Text] [Related]

  • 10. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy.
    Wellington K, Goa KL.
    Drugs; 2003 Jan; 63(4):417-37. PubMed ID: 12558465
    [Abstract] [Full Text] [Related]

  • 11. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
    James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I, Collins S, McLaren D, O'Sullivan J, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown J, Chakraborti P, Russell M, Billingham L.
    Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
    [Abstract] [Full Text] [Related]

  • 12. Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer.
    McCormack PL, Plosker GL.
    Drugs; 2006 Jul; 66(5):711-28. PubMed ID: 16620148
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
    Cristino J, Finek J, Jandova P, Kolek M, Pásztor B, Giannopoulou C, Qian Y, Brezina T, Lothgren M.
    J Med Econ; 2017 Aug; 20(8):799-812. PubMed ID: 28485692
    [Abstract] [Full Text] [Related]

  • 14. Bisphosphonates for breast cancer.
    Pavlakis N, Schmidt R, Stockler M.
    Cochrane Database Syst Rev; 2005 Jul 20; (3):CD003474. PubMed ID: 16034900
    [Abstract] [Full Text] [Related]

  • 15. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
    Raje N, Roodman GD, Willenbacher W, Shimizu K, García-Sanz R, Terpos E, Kennedy L, Sabatelli L, Intorcia M, Hechmati G.
    J Med Econ; 2018 May 20; 21(5):525-536. PubMed ID: 29480139
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom.
    Botteman MF, Meijboom M, Foley I, Stephens JM, Chen YM, Kaura S.
    Eur J Health Econ; 2011 Dec 20; 12(6):575-88. PubMed ID: 20809091
    [Abstract] [Full Text] [Related]

  • 17. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
    Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P, Gittoes N.
    Health Technol Assess; 2016 Oct 20; 20(78):1-406. PubMed ID: 27801641
    [Abstract] [Full Text] [Related]

  • 18. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
    Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, Novotny PJ, Borah BJ.
    J Clin Oncol; 2017 Dec 10; 35(35):3949-3955. PubMed ID: 29023215
    [Abstract] [Full Text] [Related]

  • 19. Bisphosphonates and other bone agents for breast cancer.
    Wong MH, Stockler MR, Pavlakis N.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD003474. PubMed ID: 22336790
    [Abstract] [Full Text] [Related]

  • 20. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
    Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J.
    Cancer Invest; 2002 Feb 15; 20 Suppl 2():45-54. PubMed ID: 12442349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.